<DOC>
	<DOCNO>NCT00920075</DOCNO>
	<brief_summary>The investigator earlier show treatment patient juvenile osteoporosis alendronate ( Fosamax ) 12 month increase bone density without side effect . In open label study ( 10 patient ) double blind , crossover study ( 11 patient alendronate 11 patient placebo ) , investigator observe alendronate increase bone density significantly placebo ( calcium vitamin D ) increase minimally . These trial complete . Thus , post study design evaluate current status bone density fracture patient discontinued alendronate treatment . No treatment involve .</brief_summary>
	<brief_title>Alendronate Juvenile Osteoporosis</brief_title>
	<detailed_description>With availability Dual Energy X-ray Absorptiometry ( DXA ) , juvenile osteoporosis recognize diagnosed recent year . The disease result either diminished bone formation increase bone removal ( resorption ) result low bone density fracture . No specific drug therapy recommend juvenile osteoporosis . In open label study , early show alendronate treatment ( 10 patient ) 12 month increase bone density without side effect . Subsequently , double blind , crossover study , confirm alendronate treatment ( 11 patient ) increase bone density significantly whereas , placebo ( 11 patient calcium vitamin D ) , increase bone density minimally . There side effect . These patient treat alendronate 12 month clinical trial complete . We therefore , design post study evaluate current status bone density fracture history participant discontinuation ( 1-6 year ) alendronate treatment . Available participant , complete earlier study , schedule one time clinic visit . Measurements include DXA bone density measurement spine hip , urinalysis blood work . No treatment involve .</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Alendronate</mesh_term>
	<criteria>Participated earlier clinical study ; Completed earlier open label double blind study ; Availability participate post study ; Male female child earlier participated clinical trial ; AND Parental consent ( patient assent age 12 year ) participate study . Participant 's consent complete 18 year age time clinic visit . Not participate earlier clinical study ; Not complete early trial ; OR Pregnancy .</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>Juvenile Osteoporosis</keyword>
	<keyword>Bone Mineral Density</keyword>
	<keyword>Fosamax</keyword>
	<keyword>Dual Energy X-Ray Absorptiometry</keyword>
	<keyword>Fracture</keyword>
</DOC>